Sincrolab Gets €100K Boost from Eoniq.fund for AI Therapy

Sincrolab, a pioneer in AI-driven cognitive therapy, has secured a significant €100,000 investment from Eoniq.fund. This latest capital injection underscores the growing confidence in Sincrolab's innovative approach to digital therapeutics, particularly for conditions like ADHD in children and cognitive decline in adults. The funding will be instrumental in accelerating the company's technological advancements and expanding its market reach.

The digital health sector is experiencing robust growth, with AI integration becoming a key differentiator. Sincrolab's platform stands out by offering personalized cognitive treatment plans, adapting dynamically to individual patient needs. This adaptive capability is crucial in a market where generic solutions often fall short. The company's CE Class IIa certification for its ADHD digital solution further validates its commitment to clinical efficacy and regulatory compliance, a vital aspect for adoption within healthcare systems.

This new funding round brings Eoniq.fund's total investment in Sincrolab to €335,000, reflecting a deepening strategic partnership. The deal was finalized with a pre-money valuation of €8.5 million, signaling strong investor belief in Sincrolab's future trajectory. The company, headquartered in Malaga, Spain, currently employs a dedicated team of 12 professionals.

Sincrolab has already made substantial inroads, collaborating with over 800 therapists and integrating its solutions into more than 100 specialized centers. This established network provides a solid foundation for future expansion. The company's strategic objectives include fortifying its core technology, entering new geographical markets, and forging crucial alliances with medical and pharmaceutical entities to champion evidence-based digital therapies.

The investment from Eoniq.fund arrives at a pivotal moment for digital therapeutics. The global digital health market is projected to reach hundreds of billions of dollars in the coming years, driven by increasing demand for accessible, personalized, and cost-effective healthcare solutions. AI's role in diagnostics, treatment, and patient monitoring is central to this expansion, making companies like Sincrolab well-positioned to capture significant market share.

This funding will empower Sincrolab to enhance its AI algorithms, refine user interfaces for both patients and clinicians, and scale its operations. The focus on cognitive therapy addresses a critical unmet need, offering scalable solutions that can alleviate pressure on traditional healthcare services. The continued support from Eoniq.fund highlights the venture capital community's increasing appetite for innovative healthtech ventures that demonstrate clear clinical and commercial potential.